<DOC>
	<DOCNO>NCT02598856</DOCNO>
	<brief_summary>Opioid overdose last decade count 230 untimely death annually Norway . The government currently implement strategy combat epidemic . Among action promote strategy distribution naloxone intranasal administration . Such administration naloxone currently implement try around world , little do pharmacologically study new route administration well know drug , 3 open label randomize control trial ( RCTs ) conduct . A recent guideline WHO community management opioid overdose comprehensive review many aspect investigator cover research . Regarding dosage , rout administration naloxone care patient pre hospital setting . The WHO call nasal formulation high concentration , well focus current wide spread label use nasal naloxone problem identify several research question critical importance low evidence.The current study , together research group 's previous future study , aim provide data development medicinal product marketing authorisation use pre-hospital overdoses . This contribute public health measure opioid user around .</brief_summary>
	<brief_title>Bioavailability Nasal Naloxone Injected Naloxone Compared</brief_title>
	<detailed_description />
	<mesh_term>Drug Overdose</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<criteria>In order participate study subject must meet follow inclusion criterion : Provision sign write informed consent ECG without pathological abnormality Have BMI range 18.5 26.0 kg/m Female subject child bear potential must use high efficacy contraception . For purpose study acceptable contraception define sterilization , oral contraceptive , patch , implant , vaginal ring , hormonal IUD copper IUD study last visit . Laboratory value within reference value follow haematology biochemistry test : Haemoglobin Creatinine ASAT ALAT Gamma GT In order participate study subject must meet follow exclusion criterion : use medication regular basis , include regular use nasal spray form . History prior drug allergy local nasal disease nasal surgery last 2 month Pregnant breast feeding woman . A serum HCG 3 U/L must demonstrate female childbearing potential Screening Visit . Current drug alcohol abuse , opinion Investigator preclude participation study . Having receive another new medical chemical entity ( define compound approve marketing ) participate clinical study include drug treatment within 3 month administration investigational product study . Hypersensitivity naloxone excipients . Investigator considers subject unlikely comply study procedure , restriction and/or requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Emergency Treatment</keyword>
	<keyword>Morphine Derivates</keyword>
	<keyword>Heroin</keyword>
	<keyword>Antidotes</keyword>
	<keyword>Administration , Intravenous</keyword>
	<keyword>Pharmacology</keyword>
	<keyword>Naloxone</keyword>
	<keyword>Healthy volunteer</keyword>
	<keyword>Administration , intramuscular</keyword>
	<keyword>Administration , intranasal</keyword>
</DOC>